Citadel Advisors’s Epirus Biopharmaceuticals EPRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
– Sell
-10,359
Closed -$28K – 8196
2016
Q1
$28K Sell
10,359
-4,176
-29% -$11.7K ﹤0.01% 6572
2015
Q4
$45K Buy
+14,535
New +$65.5K ﹤0.01% 7604
2015
Q3
– Sell
-40,383
Closed -$230K – 9947
2015
Q2
$230K Buy
+40,383
New +$276K ﹤0.01% 6292

Other funds holding EPRS

Citadel Advisors's EPRS Position: Q2 2016 in Review

Citadel Advisors sold out of Epirus Biopharmaceuticals (EPRS) in Q2 2016, closing a stake of 10,359 shares — an estimated $28K sold.

Citadel Advisors first reported a position in EPRS in Q2 2015 and held it in 3 quarters. The position peaked at $230K in Q2 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

  • Citadel Advisors reported no remaining Epirus Biopharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Citadel Advisors sold 10,359 Epirus Biopharmaceuticals shares in Q2 2016, an estimated $28K.
  • Citadel Advisors first reported a position in Epirus Biopharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Citadel Advisors's Epirus Biopharmaceuticals position peaked at $230K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held Epirus Biopharmaceuticals as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.